Isoprinosine

Absorption

Rapidly absorbed from GIT

Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Mouse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Chemical properties

White powder, odorless and tasteless. Soluble in water.

The Uses of Isoprinosine

Isoprinosine is a new combination of active substances for the treatment of chronic systemic diseases such as cancer. Isoprinosine is an immunomodulator; antiviral. The ratio is between 1: 2 : 2 to 1 : 3 : 3

The Uses of Isoprinosine

Isoprinosine

Indications

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Background

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

What are the applications of Application

Isoprinosine is an antiviral reagent

Biological Activity

isoprinosine is a complex of acetaminobenzoic acid, dimethylaminoisopropanol, and inosine in a 3:3:1 ratio with immunomodulatory effects.immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. immunomodulatory regimens usually have fewer side effects than existing drugs, such as less potential for creating resistance when treating microbial disease.

Mechanism of action

Isoprinosine is thought to act through a receptor for an inosine-like compound on T cell precursors. In vivo it appears to induce the production of more mature T cells and there is some evidence that it can increase the CD4:CD8 ratio in a variety of conditions. In addition, Isoprinosine enhances B-lymphocyte activity, possibly through effects on helper T cells. It also increases macrophage phagocytosis, releases cytokines that induce macrophage proliferation, including immune interferon and interleukin-1 (IL-1) and IL-2, and potentiates T-cell mitogens.

Pharmacokinetics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Clinical Use

Treatment of mucocutaneous herpes simplex, genital warts, subacute sclerosing panencephalitis

in vitro

previous study found that increasing concentrations of isoprinosine (50-400 μg/ml) could produce progressively growing inhibitory effect on hhv-1 replication. the combination of 1000 iu/ml ifn-α and isoprinosine could result in enhanced anti-hhv activity [1].

in vivo

previous study demonstrated the positive effect of isoprinosine treatment on persistent infection of balb/c mice with murine gammaherpesvirus 68. increased number of leukocytes, increased percentage of neutrophils, elevated levels of virus-neutralizing antibodies, reduced number of atypical lymphocytes and reduced virus titers were detected in the examined organs after a 14-day treatment. the positive effect of isoprinosine therapy vanished after 120-150 days [2].

Metabolism

Hepatically metabolised. The major excretion product of the inosine moiety is uric acid, while the p-acetamidobenzoic acid and N,N-dimethylamino- 2-propanol components are excreted in the urine as glucuronidated and oxidised products, respectively, as well as being excreted unchanged

Metabolism

Not Available

References

[1] majewska a, lasek w, janyst m, mynarczyk g. in vitro infibition of hhv-1 replication by inosine pranobex and interferon-α. acta pol pharm. 2016 may-jun;73(3):637-44.
[2] janíková o, anicová l, briestenská k, mistríková j. the effect of isoprinosine treatment on persistent infection of balb/c mice infected with murine gammaherpesvirus 68. acta virol. 2017;61(1):32-38. doi: 10.4149/av_2017_01_32.
[3] beran j, alapová e, pajdel m; isoprinosine study (ewo iso-2014/1) team. inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a phase 4, randomised, placebo-controlled, double-blind study. bmc infect dis. 2016 nov 7;16(1):648.